Navigation Links
US FDA Approves Extavia(R) - the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease
Date:8/16/2009

i>FDA approves Betaseron(R) for use after the first event suggestive of multiple sclerosis [press release]. Wayne, NJ: Berlex: 23 October 2006.
  • National Multiple Sclerosis Society website: http://www.nationalmssociety.org/about-multiple-sclerosis/who-gets-ms/index.aspx. Accessed August 12, 2009.
  • Multiple Sclerosis International Federation website. http://www.msif.org/en/about_ms/what_is_ms.html. Accessed August 12, 2009.
  • Extavia Prescribing Information, August 14, 2009.
  • Habermann, T. and Amit K. Ghosh ed. Mayo Clinic Internal Medicine Concise Textbook. Florence, KY: Informa HealthCare, 2007.
  • National Multiple Sclerosis Society website. http://www.nationalmssociety.org/about-multiple-sclerosis/what-is-ms/index.aspx. Accessed August 12, 2009.
  • Multiple Sclerosis International Federation website. http://www.msif.org/en/about_ms/symptoms.html. Accessed August 12, 2009.
  • The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. Neurology. 1993;43:655-661.
  • Betaseron (interferon beta-1b) Prescribing Information. Available online at http://berlex.bayerhealthcare.com/html/products/pi/Betaseron_PI.pdf.
  • Kappos L, Freedman MS, Polman CH, et al. Treatment with interferon beta-1b delays
    '/>"/>

  • SOURCE Novartis Pharmaceuticals Corporation
    Copyright©2009 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related medicine technology :

    1. Video: FDA Approves INVEGA(R) SUSTENNA(TM) for the Acute and Maintenance Treatment of Schizophrenia
    2. FDA Approves Tekturna HCT(R) as Initial Treatment in Patients Unlikely to Achieve Their Blood Pressure Goals With a Single Agent
    3. FDA Approves ADCIRCA(TM) (Tadalafil) Tablets for the Treatment of Pulmonary Arterial Hypertension
    4. FDA Approves Vanda Pharmaceuticals Fanapt(TM) for the Treatment of Schizophrenia
    5. FDA Approves an Expanded Indication for Peginterferon-Based Combination Therapy for Patients With Chronic Hepatitis C
    6. FDA Approves LUSEDRA(TM) (fospropofol disodium) Injection for Monitored Anesthesia Care (MAC) Sedation
    7. FDA Approves Tapentadol Immediate-Release Tablets for Relief of Moderate to Severe Acute Pain
    8. FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder
    9. FDA Approves Rapid-Acting Insulin Apidra(R) for Treatment of Children with Diabetes
    10. FDA Approves Bayer HealthCares Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A
    11. F.D.A. Approves SANCUSO(R), the First and Only Patch for Preventing Nausea and Vomiting in Cancer Patients Undergoing Chemotherapy
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/23/2015)... , Jan. 23, 2015  A new analysis of ... D 2015 enrollment data shows that 81 percent of ... access and extra discounts at certain pharmacies. The findings ... "Preferred pharmacy plans are now the foundation of Medicare ...
    (Date:1/23/2015)... , Jan. 23, 2015 /PRNewswire/-- Harwood Feffer LLP ( ... of directors of Advaxis, Inc. ("Advaxis" or the "Company") ... has breached its fiduciary duties to shareholders. ... an investing website reporting that Advaxis had misrepresented the ...
    (Date:1/23/2015)... 2015  Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT), announced that the ... Lixte,s lead compound, LB‑100, is being conducted, has been expanded ... Kovach , M.D., the founder and President of Lixte, said ... a single site. Accrual of patients, however, was slower than ...
    Breaking Medicine Technology:New Analysis: 81 Percent of Medicare Part D Seniors Choose "Preferred Pharmacy" Plans in 2015 2Harwood Feffer LLP Announces Investigation of Advaxis, Inc. 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3
    ... Dec. 2, 2010 United Seating & Mobility (USM) ... suppliers, is excited to announce today that it has finalized ...   The transaction applies to Fridley, MN serving ... Milwaukee Area, and Appleton, WI; RehabTECH will continue to operate ...
    ... (OTC Bulletin Board: CDXC ), a leader ... research services, today announced that it has entered into ... to supply analytical reference standards, quality control methods and ... raw materials and finished goods. "With increasing ...
    Cached Medicine Technology:ChromaDex Partners With Kappa Bioscience to Provide Quality Control Methods, Tools and Services for Vitamin K2 2
    (Date:1/22/2015)... NJ (PRWEB) January 22, 2015 Joan ... and keynote speaker at the upcoming 32nd Annual ... ACCME-accredited Physicians’ Education Resource®, LLC (PER®) , shares ... would have gone undetected if she had not followed ...
    (Date:1/22/2015)... (PRWEB) January 22, 2015 Yesterday, ... Bonilla (D-Concord) and Kristin Olsen (R-Modesto) were honored ... leadership in advancing biotechnology, biomedical science, medical device ... Olsen each received the “2014 Life Sciences Champion” ...
    (Date:1/22/2015)... January 22, 2015 IsoComforter, Inc. has introduced ... with patented IsoTube design to treat specific body parts and ... most progressive and easy to use patented cold therapy machine ... sports related orthopedic and muscle injuries. IsoComforter has become ...
    (Date:1/22/2015)... Payday lending practices in four southern states worsen ... to the states that permit them, according to a ... Race and Wealth. , While they generate hundreds of ... the same time substantially depress economic activity, according to ...
    (Date:1/22/2015)... As interest in the value of spiritual support as ... Rev. Eric J. Hall , president and CEO of the ... the keynote speaker on January 27 at an international summit ... The conference, “Hope and Resilience: Innovative and Interdisciplinary Spiritual Care,” ...
    Breaking Medicine News(10 mins):Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 5Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 6Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 3
    ... years ago, the first Ronald McDonald House(R) opened its ... home" for families with seriously ill children. Today, McDonald,s(R) ... celebration to commemorate this important milestone and their long-standing ... , , "For 35 years, local McDonald,s franchisees ...
    ... For more than 30 years, consumers have benefited from the ... effects of the sun, including sun burn, premature skin aging, ... efficacy of sunscreen products have been thoroughly studied and tested ... is an extensive body of credible scientific research that demonstrates ...
    ... scientists, patients and members of the biotech industry from around ... unique research center on muscular dystrophy -- the Senator Paul ... , Established last year and based at Boston Biomedical Research ... Center and the only center in the world to focus ...
    ... Discovery may help explain why disease runs in families, , ... to inherited testicular germ-cell cancer has been identified by scientists ... contributes to our understanding of why testicular germ-cell cancer appears ... said in an agency news release. "The findings may also ...
    ... published in the July issue of The Journal ... (PET) scans in mice can be used to determine ... working as intended. Researchers successfully used PET and a ... with aggressive breast cancerin breast cancer cells before and ...
    ... NEW BRUNSWICK, N.J. and DUBLIN, July 2 Johnson & ... (NYSE: ELN ) today announced a definitive agreement ... assets and rights of Elan related to its Alzheimer,s Immunotherapy ... addition, Johnson & Johnson, through its affiliate, will invest $1 ...
    Cached Medicine News:Health News:Ronald McDonald House Charities(R) (RMHC(R)) and McDonald's(R) Seek Inspiring Stories Through New 'Share.Give.Hope.' Campaign 2Health News:Ronald McDonald House Charities(R) (RMHC(R)) and McDonald's(R) Seek Inspiring Stories Through New 'Share.Give.Hope.' Campaign 3Health News:Statement by John Bailey, Chief Scientist The Personal Care Products Council, Response to EWG's 2009 Sunscreen Report 2Health News:Statement by John Bailey, Chief Scientist The Personal Care Products Council, Response to EWG's 2009 Sunscreen Report 3Health News:Statement by John Bailey, Chief Scientist The Personal Care Products Council, Response to EWG's 2009 Sunscreen Report 4Health News:Statement by John Bailey, Chief Scientist The Personal Care Products Council, Response to EWG's 2009 Sunscreen Report 5Health News:Successful Beginning for Wellstone Muscular Dystrophy Center at Boston Biomedical Research Institute 2Health News:Another Genetic Link to Testicular Cancer Is Found 2Health News:Study shows PET can measure effectiveness of novel breast cancer treatment 2Health News:Johnson & Johnson and Elan Corporation plc Announce Definitive Agreement for Alzheimer's Immunotherapy Program and Equity Investment 2Health News:Johnson & Johnson and Elan Corporation plc Announce Definitive Agreement for Alzheimer's Immunotherapy Program and Equity Investment 3Health News:Johnson & Johnson and Elan Corporation plc Announce Definitive Agreement for Alzheimer's Immunotherapy Program and Equity Investment 4Health News:Johnson & Johnson and Elan Corporation plc Announce Definitive Agreement for Alzheimer's Immunotherapy Program and Equity Investment 5
    ... Performance beyond your investment., ,The Centiva/5 Critical ... and time demands of the critical care environment. ... in mind combining a compact size with high ... up valuable space around the patients bed and ...
    ... Although other treatments for ,ED (e.g. ... used today, ,Vacuum Therapy is ... and their physicians ,because of the very ... should be used as a daily ,exercise ...
    ... is combining a lightweight mesh material with the ... hernia plug which stands for a high patient ... material is included in Premilene Mesh LP Self-Forming ... for a softer and less bulky Plug Premilene ...
    ... a mesh plug to treat large or ... hernias and femoralhernias. The self-expanding plug perfectly ... completely. Premilene Mesh Self-Forming Plug is a ... Mesh. The plug corresponds with all properties ...
    Medicine Products: